Trospium chloride - Generic Drug Details
✉ Email this page to a colleague
What are the generic sources for trospium chloride and what is the scope of patent protection?
Trospium chloride
is the generic ingredient in four branded drugs marketed by Allergan, Actavis Labs Fl Inc, Granules, Padagis Us, Upsher Smith Labs, Utopic Pharms, Apotex, Glenmark Pharms Ltd, Heritage Pharms Inc, Invagen Pharms, Macleods Pharms, Zameer Pharms, and Bristol-myers, and is included in fifteen NDAs. There are eleven patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.Nineteen suppliers are listed for this compound.
Summary for trospium chloride
| US Patents: | 11 |
| Tradenames: | 4 |
| Applicants: | 13 |
| NDAs: | 15 |
| Finished Product Suppliers / Packagers: | 19 |
| Raw Ingredient (Bulk) Api Vendors: | 1 |
| Clinical Trials: | 29 |
| Patent Applications: | 4,566 |
| Drug Prices: | Drug price trends for trospium chloride |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for trospium chloride |
| What excipients (inactive ingredients) are in trospium chloride? | trospium chloride excipients list |
| DailyMed Link: | trospium chloride at DailyMed |
Recent Clinical Trials for trospium chloride
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| European Group for Research In Schizophrenia | PHASE3 |
| University Medical Center Groningen | PHASE3 |
| University of Texas Southwestern Medical Center | EARLY_PHASE1 |
Pharmacology for trospium chloride
| Drug Class | Cholinergic Muscarinic Antagonist |
| Mechanism of Action | Cholinergic Muscarinic Antagonists |
Anatomical Therapeutic Chemical (ATC) Classes for trospium chloride
Paragraph IV (Patent) Challenges for TROSPIUM CHLORIDE
| Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
|---|---|---|---|---|---|---|
| SANCTURA XR | Extended-release Capsules | trospium chloride | 60 mg | 022103 | 1 | 2009-03-02 |
US Patents and Regulatory Information for trospium chloride
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bristol-myers | COBENFY | trospium chloride; xanomeline tartrate | CAPSULE;ORAL | 216158-002 | Sep 26, 2024 | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Heritage Pharms Inc | TROSPIUM CHLORIDE | trospium chloride | TABLET;ORAL | 204945-001 | Aug 30, 2016 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Bristol-myers | COBENFY | trospium chloride; xanomeline tartrate | CAPSULE;ORAL | 216158-002 | Sep 26, 2024 | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for trospium chloride
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Allergan | SANCTURA XR | trospium chloride | CAPSULE, EXTENDED RELEASE;ORAL | 022103-001 | Aug 3, 2007 | ⤷ Start Trial | ⤷ Start Trial |
| Allergan | SANCTURA XR | trospium chloride | CAPSULE, EXTENDED RELEASE;ORAL | 022103-001 | Aug 3, 2007 | ⤷ Start Trial | ⤷ Start Trial |
| Allergan | SANCTURA XR | trospium chloride | CAPSULE, EXTENDED RELEASE;ORAL | 022103-001 | Aug 3, 2007 | ⤷ Start Trial | ⤷ Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2026 - 2027
NCE-1 Patent Challenge Dates 2026 - 2027
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch